09.21.26 -- FDA Not A Good FRAME For CDMO Inspections?

Biologics manufacturing is evolving through smarter fill technologies, onshoring, advanced automation, and data driven processes that improve efficiency, reduce risk, and protect product value.

Discover how safety‑by‑design principles in chemical synthesis help control exothermic reactions, reduce scale‑up risk, and enable safer, more reliable manufacturing of complex drug substances.

ADCs require early-stage analytics to manage complex interactions among components, enabling better characterization, reduced development risk, and more reliable progression.

The shift from static platforms to knowledge-driven development helps biopharma teams manage BsAb complexity, accelerate analytical, purification, and formulation development, and improve IND readiness.

Early host selection shapes biological activity, manufacturing costs, and commercial flexibility. Evaluating trade-offs early prevents costly redevelopment and optimizes downstream purification.

Scaling mammalian biologics relies on mirrored infrastructure and single-use technologies to streamline tech transfer and enable cost-efficient commercialization.

Late-stage therapy trials demand strict execution. Learn how local handling variations escalate into global risks and how early standardization safeguards therapeutic integrity and compliance.

Integrated analytics address multispecific antibody CMC challenges, accelerating timelines, reducing risk, and improving decisions through mechanism-driven bioassays, automation, and case studies.

By leveraging expertise across a global network and executing a streamlined, rapid technology transfer, see how we were able to enable a highly data-driven approach to clone selection.

As biologics manufacturing globalizes, companies must balance cost, capacity, risk, and control when choosing between European and Asian supply bases for clinical and commercial success.

Discover how chemomic analysis unlocks full DEL datasets to reveal SAR trends, mechanism clues, and risks to help teams make clearer, data‑driven decisions and build stronger hit‑to‑lead foundations.

Operational excellence meets ethical stewardship. Data-driven strategies and renewable energy integration are shaping a responsible future for global manufacturing and community engagement.

Assimilate how surging demand for GLP-1 and other therapeutics is transforming fill/finish capacity and regulatory standards. Learn how CDMOs are adapting to the complex needs of emerging modalities.

Navigate the challenging path from concept to clinical reality by partnering with an experienced CDMO that can provide the regulatory, clinical, and CMC expertise needed to move your therapeutic forward.

Uncover how lyophilization revolutionizes biologic drug manufacturing and ensures potent, stable treatments for complex diseases.

Skin delivery platforms expand therapies by boosting convenience, stability, and adherence. Integrated formulation, device, and manufacturing development is key to confidently scale.